KYTX vs. BCYC, MNMD, DNTH, KURA, MRVI, RLAY, VECT, KROS, ARVN, and MAZE
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Bicycle Therapeutics (BCYC), Mind Medicine (MindMed) (MNMD), Dianthus Therapeutics (DNTH), Kura Oncology (KURA), Maravai LifeSciences (MRVI), Relay Therapeutics (RLAY), VectivBio (VECT), Keros Therapeutics (KROS), Arvinas (ARVN), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry.
Kyverna Therapeutics vs. Its Competitors
Bicycle Therapeutics (NASDAQ:BCYC) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.
86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 22.0% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Kyverna Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Kyverna Therapeutics' return on equity.
Bicycle Therapeutics received 134 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. Likewise, 70.53% of users gave Bicycle Therapeutics an outperform vote while only 63.16% of users gave Kyverna Therapeutics an outperform vote.
Bicycle Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500.
Bicycle Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 187.69%. Kyverna Therapeutics has a consensus price target of $18.50, suggesting a potential upside of 434.68%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Bicycle Therapeutics.
Kyverna Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bicycle Therapeutics had 9 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 11 mentions for Bicycle Therapeutics and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.56 beat Bicycle Therapeutics' score of 0.53 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.
Summary
Bicycle Therapeutics beats Kyverna Therapeutics on 11 of the 19 factors compared between the two stocks.
Get Kyverna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kyverna Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KYTX) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy KYTX Stock Free KYTX Stock Alerts